EDGEWISE THERAPEUTICS INC (EWTX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for EWTX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| EWTX | DIRECTOR; Director; Chairperson | 68 | ["BridgeBio Pharma, Inc., Senior Advisor","Senior Advisor to BridgeBio Pharma, Inc.","Managing Director at Cervantes Life Science Partners, LLC","President and Chief Executive Officer at Nodality, Inc.","Executive Vice President and Chief Operating Officer at Onyx Pharmaceuticals, Inc.","General partner at Red Rock Capital Management","Senior Vice President and Chief Financial Officer at COR Therapeutics, Inc.","Vice President and Chief Financial Officer at Flextronics","Vice President and Treasurer of The Cooper Companies","Served on the boards of multiple biotechnology companies","audit committee financial expert","financial sophistication"] | ["Audit","Compensation"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MIRM | Senior Advisor | 68 | ["Over 20 years of executive management experience in the pharmaceutical, biotechnology and venture capital industries.","Former President and Chief Executive Officer of Nodality, Inc.","Held senior-level positions at Onyx Pharmaceuticals, Inc.","General Partner at Red Rock Capital Management.","Senior Vice President and Chief Financial Officer at COR Therapeutics Inc.","Chief Financial Officer at Flextronics, Inc."] | [] | 2026 |
| PCRX | Senior Advisor to BridgeBio Pharma, Inc.; and former Chief Executive Officer, Nodality, Inc.; Independent Board Chair; Independent Director | 67 | ["Over 35 years of leadership in pharmaceutical, biotechnology and venture capital", "Contributes to the board\u2019s oversight of strategic growth initiatives and capital allocation strategies", "Corporate governance experience gained through service on public company boards", "Proven track record in leading corporate functions and teams responsible for commercialization of drugs and treatments", "Brings substantial insights into business development and growth strategies", "CFO of COR Therapeutics, oversaw rapid growth to commercially launching a successful cardiovascular drug treatment"] | ["Audit", "People & Compensation", "Nominating, Governance & Sustainability", "Nominating", "Governance and Sustainability", "Nominating, Governance and Sustainability Committee"] | 2025 |
| ACAD | Director | 61 | [] | [] | 2019 |